Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887877 | 0.92 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL5888082 | 0.90 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL5229719 | 0.83 | HPGD (0.49) | SLC6A2SLC6A4SLC6A3KCNH2TSHR | |
| SCHEMBL5887717 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL5200972 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2TSHR | |
| SCHEMBL5224404 | 0.82 | HPGD (0.51) | SLC6A2SLC6A4SLC6A3KCNH2TSHR | |
| SCHEMBL5200447 | 0.82 | HPGD (0.51) | SLC6A2SLC6A4SLC6A3KCNH2TSHR | |
| SCHEMBL5888146 | 0.82 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL5266110 | 0.78 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL5263948 | 0.77 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122683-B2 | Amides useful as monoamine re-uptake inhibitors | PFIZER INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | ADRB3, AOC3, HRH4 | SLC6A2 33/4885SLC6A4 49/4885SLC6A3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.